FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3217382821> ?p ?o ?g. }

• W3217382821 abstract "<b>Introduction:</b> COVID-19 is often complicated by hypoxemic respiratory failure, resulting from widespread capillary leak. The kinase inhibitor imatinib may protect the endothelial barrier and reverse pulmonary capillary leak. <b>Methods:</b> This was a randomized, double-blind, placebo-controlled trial. Hospitalized COVID-19 patients requiring supplemental oxygen were randomized to oral imatinib (800mg loading dose, followed by 400mg daily for 9 days) or placebo on top of standard care. The primary outcome was time to liberation from supplemental oxygen (>48 hours) and alive during a 28-day period. Secondary outcomes included 28-day mortality and the need for invasive ventilation. <b>Results:</b> 385 patients (median age 64 (range 28-93) years) were included in the analysis. There was no difference in the primary outcome between the groups, i.e. the time to liberation from ventilation and supplemental oxygen (unadjusted hazard ratio [HR] 0.95; 95%CI 0.76-1.20). Mortality was 8% in the imatinib group, compared to 14% in the placebo group (unadjusted HR 0.51; 95%CI 0.27-0.95). After adjustment for baseline imbalances the HR for mortality was 0.52 (95%CI 0.26-1.05) (<i>Figure 1</i>). The median duration of invasive ventilation was 7 days in the imatinib group versus 12 days in the placebo group (p=0.008). The number of ventilator-free days was 22 (IQR, 14 to 26 days) in the imatinib group versus 9 (IQR, 0 to 23 days) in the placebo group (p=0·018). No imatinib-associated adverse events were observed. <b>Conclusion:</b> Although imatinib did not affect the primary outcome, the observed benefit in mortality and duration of mechanical indicate that imatinib may confer clinical benefit in COVID19." @default.
• W3217382821 created "2021-12-06" @default.
• W3217382821 creator A5001270344 @default.
• W3217382821 creator A5005140861 @default.
• W3217382821 creator A5008754128 @default.
• W3217382821 creator A5009215641 @default.
• W3217382821 creator A5009466732 @default.
• W3217382821 creator A5012383056 @default.
• W3217382821 creator A5013315693 @default.
• W3217382821 creator A5014714859 @default.
• W3217382821 creator A5016558868 @default.
• W3217382821 creator A5017147924 @default.
• W3217382821 creator A5019676794 @default.
• W3217382821 creator A5019687181 @default.
• W3217382821 creator A5020257336 @default.
• W3217382821 creator A5020771677 @default.
• W3217382821 creator A5021989075 @default.
• W3217382821 creator A5023222272 @default.
• W3217382821 creator A5023335403 @default.
• W3217382821 creator A5025013942 @default.
• W3217382821 creator A5029058509 @default.
• W3217382821 creator A5037071959 @default.
• W3217382821 creator A5037628837 @default.
• W3217382821 creator A5038057260 @default.
• W3217382821 creator A5038304058 @default.
• W3217382821 creator A5040003828 @default.
• W3217382821 creator A5040501276 @default.
• W3217382821 creator A5041574334 @default.
• W3217382821 creator A5042074105 @default.
• W3217382821 creator A5042723808 @default.
• W3217382821 creator A5043252219 @default.
• W3217382821 creator A5043317541 @default.
• W3217382821 creator A5045574909 @default.
• W3217382821 creator A5046254448 @default.
• W3217382821 creator A5047839612 @default.
• W3217382821 creator A5050361086 @default.
• W3217382821 creator A5050541049 @default.
• W3217382821 creator A5050844916 @default.
• W3217382821 creator A5052380807 @default.
• W3217382821 creator A5052511900 @default.
• W3217382821 creator A5054286177 @default.
• W3217382821 creator A5059514933 @default.
• W3217382821 creator A5060335466 @default.
• W3217382821 creator A5060747022 @default.
• W3217382821 creator A5061451352 @default.
• W3217382821 creator A5061666793 @default.
• W3217382821 creator A5061829652 @default.
• W3217382821 creator A5062432201 @default.
• W3217382821 creator A5063396131 @default.
• W3217382821 creator A5067044422 @default.
• W3217382821 creator A5067268799 @default.
• W3217382821 creator A5068697800 @default.
• W3217382821 creator A5077534860 @default.
• W3217382821 creator A5078120251 @default.
• W3217382821 creator A5079393024 @default.
• W3217382821 creator A5080851763 @default.
• W3217382821 creator A5082960379 @default.
• W3217382821 creator A5083654901 @default.
• W3217382821 creator A5085972272 @default.
• W3217382821 creator A5086646404 @default.
• W3217382821 creator A5089585844 @default.
• W3217382821 date "2021-09-05" @default.
• W3217382821 modified "2023-10-04" @default.
• W3217382821 title "Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19" @default.
• W3217382821 doi "https://doi.org/10.1183/13993003.congress-2021.oa4119" @default.
• W3217382821 hasPublicationYear "2021" @default.
• W3217382821 type Work @default.
• W3217382821 sameAs 3217382821 @default.
• W3217382821 citedByCount "0" @default.
• W3217382821 crossrefType "proceedings-article" @default.
• W3217382821 hasAuthorship W3217382821A5001270344 @default.
• W3217382821 hasAuthorship W3217382821A5005140861 @default.
• W3217382821 hasAuthorship W3217382821A5008754128 @default.
• W3217382821 hasAuthorship W3217382821A5009215641 @default.
• W3217382821 hasAuthorship W3217382821A5009466732 @default.
• W3217382821 hasAuthorship W3217382821A5012383056 @default.
• W3217382821 hasAuthorship W3217382821A5013315693 @default.
• W3217382821 hasAuthorship W3217382821A5014714859 @default.
• W3217382821 hasAuthorship W3217382821A5016558868 @default.
• W3217382821 hasAuthorship W3217382821A5017147924 @default.
• W3217382821 hasAuthorship W3217382821A5019676794 @default.
• W3217382821 hasAuthorship W3217382821A5019687181 @default.
• W3217382821 hasAuthorship W3217382821A5020257336 @default.
• W3217382821 hasAuthorship W3217382821A5020771677 @default.
• W3217382821 hasAuthorship W3217382821A5021989075 @default.
• W3217382821 hasAuthorship W3217382821A5023222272 @default.
• W3217382821 hasAuthorship W3217382821A5023335403 @default.
• W3217382821 hasAuthorship W3217382821A5025013942 @default.
• W3217382821 hasAuthorship W3217382821A5029058509 @default.
• W3217382821 hasAuthorship W3217382821A5037071959 @default.
• W3217382821 hasAuthorship W3217382821A5037628837 @default.
• W3217382821 hasAuthorship W3217382821A5038057260 @default.
• W3217382821 hasAuthorship W3217382821A5038304058 @default.
• W3217382821 hasAuthorship W3217382821A5040003828 @default.
• W3217382821 hasAuthorship W3217382821A5040501276 @default.
• W3217382821 hasAuthorship W3217382821A5041574334 @default.
• W3217382821 hasAuthorship W3217382821A5042074105 @default.
• W3217382821 hasAuthorship W3217382821A5042723808 @default.
• W3217382821 hasAuthorship W3217382821A5043252219 @default.
• W3217382821 hasAuthorship W3217382821A5043317541 @default.

• next